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Abstract
Background: Psychometric properties of two measures of psychological well-being were evaluated for
adults with growth hormone deficiency (GHD): the General Well-being Index, (GWBI) – British version
of the Psychological General Well-being Index, and the 12-item Well-being Questionnaire (W-BQ12).
Methods: Reliability, structure and other aspects of validity were investigated in a cross-sectional study
of 157 adults with treated or untreated GHD, and sensitivity to change in a randomised placebo-controlled
study of three months' growth hormone (GH) withdrawal from 12 of 21 GH-treated adults.
Results:  Very high completion rates were evidence that both questionnaires were acceptable to
respondents. Factor analyses did not indicate the existence of useful GWBI subscales, but confirmed the
validity of calculating a GWBI Total score. However, very high internal consistency reliability (Cronbach's
alpha = 0.96, N = 152), probably indicated some item redundancy in the 22-item GWBI. On the other
hand, factor analyses confirmed the validity of the three W-BQ12 subscales of Negative Well-being,
Energy, and Positive Well-being, each having excellent internal reliability (alphas of 0.86, 0.86 and 0.88,
respectively, N from 152 to 154). There was no sign of item redundancy in the highly acceptable
Cronbach's alpha of 0.93 (N = 148) for the whole W-BQ12 scale. Whilst neither questionnaire found
significant differences between GH-treated and non-GH-treated patients, there were correlations (for
GH-treated patients) with duration of GH treatment for GWBI Total (r = -0.36, p = 0.001, N = 85), W-
BQ12 Total (r = 0.35, p = 0.001, N = 88) and for all W-BQ12 subscales: thus the longer the duration of
GH treatment (ranging from 0.5 to 10 years), the better the well-being. Both questionnaires found that
men had significantly better overall well-being than women. The W-BQ12 was more sensitive to change
than the GWBI in the GH-Withdrawal study. A significant between-group difference in change in W-BQ12
Energy scores was found [t(18) = 3.25, p = 0.004, 2-tailed]: patients withdrawn from GH had reduced
energy at end-point. The GWBI found no significant change.
Conclusion: The W-BQ12 is recommended in preference to the GWBI to measure well-being in adult
GHD: it is considerably shorter, has three useful subscales, and has greater sensitivity to change.
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Background
The physical symptoms of adult growth hormone defi-
ciency (GHD) include abnormal body composition with
reduced lean body mass and increased central adiposity;
reduced muscle strength and exercise performance [1].
However, adults with untreated GHD report symptoms of
reduced psychological well-being including low energy,
tiredness, irritability [2], anxiety, depression and mood
swings [3] and it has been said that "psychological aspects
may be at least as, if not more, important" than physiolog-
ical [4]. To measure the effects of growth hormone (GH)
treatment sensitive measures of patient-reported out-
comes, such as quality of life (QoL), health status and psy-
chological well-being, are also required in addition to
measuring physiological outcomes. Condition-specific
QoL measures in adult GHD exist [5,6], but QoL is not
equivalent to health status or well-being, although often
reported as such [7].
The questionnaire most commonly employed to measure
psychological well-being in adult GHD has been the
generic 22-item Psychological General Well-being Index
(PGWB) [8], with six subscales (Anxiety, Depression, Gen-
eral Health, Positive Well-being, Self-control and Vitality),
and a Total score. Results of randomised placebo-control-
led trials providing GH treatment to adults with GHD
have been mixed. In some studies the PGWB found no sig-
nificant change [9-11], but others found, after six months'
GH-treatment, significant improvement in Depression
[12]; Vitality and Total well-being [13]; General Health,
Positive Well-being, Vitality and Total well-being [14].
Longer-term open-label studies of GH treatment have
found improvements in most or all PGWB variables [15-
17]. Those who continued with GH therapy over 9 years
had significant increases in Vitality, but those who discon-
tinued GH had significant decreases in General Health
over the same period [18]. Some were British studies
[9,12,14,15,18] but used the PGWB, although this Amer-
ican questionnaire does not appear to have been validated
either for use in the UK or in adult GHD. However, a Brit-
ish version of the PGWB exists: the General Well-being
Index (GWBI) [19]. This is very similar to the PGWB hav-
ing only some minor differences in vocabulary (e.g. blue
becomes sad on the British version), five response catego-
ries rather than the six, and in question order.
Validation of the GWBI, in two samples of British patients
with depression, indicated construct validity [19,20] and
high internal consistency reliability for the whole scale (in
the range 0.92 – 0.96) [19]. Ability to discriminate
between subgroups in a primary care setting has also been
demonstrated [21]. Subscales were not recommended
owing to their high inter-correlations and lack of adequate
internal consistency (alpha scores were not supplied)
[20], although alpha scores for PGWB subscales have been
reported (ranging from 0.72 (Self-control) to 0.88 (Anxi-
ety) [8]. However, more recently Gaston and Vogl investi-
gated the psychometric properties in an Australian non-
clinical population and found three significant factors
[22], rather than the six factors that might have been
expected given that the GWBI is so similar to the six-sub-
scale PGWB.
The Well-being Questionnaire (W-BQ) [23] is another
generic measure of psychological well-being. The 12-item
version, the W-BQ12, is derived from the longer W-BQ22
[23,24], and which has been used in a number of studies
to evaluate the effects of new treatments and interventions
in diabetes [23-25], a condition for which it has good
internal consistency and validity [25-27]. The W-BQ12,
however, poses less respondent burden than the W-BQ22,
and redresses an imbalance between numbers of posi-
tively worded and negatively worded items in the longer
questionnaire [28]. The W-BQ12 has been translated into
several languages, and psychometric evaluations of these
and the original English have confirmed its structure and
reliability for people with diabetes [25-27] and it also has
good psychometric properties for people with macular
disease [29].
The two studies described here presented the opportunity
to evaluate the psychometric properties of both the GWBI
and W-BQ12 in a sample of adults with GHD at a London
hospital. The first study was a cross-sectional survey of
157 adults with severe GHD, GH-treated and non-GH-
treated, to investigate reliability, factor structure, construct
and concurrent validity of the questionnaires. Sensitivity
to change was investigated in a randomised placebo-con-
trolled study of three months' withdrawal of GH treat-
m e n t  f r o m  1 2  o f  2 1  G H - t r e a t e d  a d u l t s ,  w h e r e  n i n e
continued with GH.
Methods
The questionnaires
GWBI
The GWBI has 22 questions each with five response
options (scoring from 1 to 5), but worded differently for
each question, to define the intended meaning (e.g. Dur-
ing the past two weeks, have you been waking up feeling fresh
and rested? Every day – Most days – Less than half the time –
Not often – Not at all). Half the items are positively
worded, and half negatively worded. There are no recom-
mended subscales. Scoring: The GWBI Total score is the
sum of all 22 items (after reversing the negatively-worded
items), and ranges 22 -110. Higher scores indicate worse
well-being.
W-BQ12
The 12 items of the W-BQ12 are simple statements (e.g. I
feel afraid for no reason at all), and have four responseHealth and Quality of Life Outcomes 2006, 4:16 http://www.hqlo.com/content/4/1/16
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options from 0 ('not at all') to 3 ('all the time'), identical in
all 12 items. There are three subscales of four items each:
Negative Well-being (all negatively worded items), Energy
(two positively worded and two negatively worded items)
and Positive Well-being (all positively worded). Scoring:
Subscale scores range from 0 – 12 (higher scores indicat-
ing increased mood of the subscale label). The W-BQ12
General Well-being total score is the sum of all 12 items
(after reversing the Negative Well-being item scores), and
ranges from 0 – 36 (higher scores indicating better well-
being).
Other questionnaires
Other questionnaires were also completed in these studies
including the Nottingham Health Profile [30], the Short-
form 36 (SF-36) [31], and a new hormone deficiency-spe-
cific individualised quality of life questionnaire (HDQoL)
[5], the full results for which have been reported previ-
ously [32-34].
Study 1: The cross-sectional survey
Recruitment procedures
Recruitment procedures have been fully described else-
where [32], but in brief they were as follows. Participating
patients had been diagnosed severely GH deficient as
determined by an Insulin Tolerance or Pituitary Function
Test in which insulin reduced blood glucose to ≤ 2.5
mmol/L with peak GH concentration ≤ 10 mU/L. Patients
had either received GH-replacement therapy for at least
six months immediately prior to the study or had not
received GH treatment in the previous six months; were
aged between 18–70 years; had received appropriate adre-
nal, thyroid and gonadal hormone replacement therapy
as required by their hormonal condition, for at least 12
months prior to the study. Patients might have had adult
or childhood onset of GHD. Exclusion criteria were diabe-
tes mellitus, active malignancy or pregnancy.
Statistical analyses
Normality issues
Normality of distributions was investigated through
standardised z (skew) values [35]. Some questionnaire
item distributions were skewed, and finding transforma-
tions for these variables that did not adversely affect nor-
mal distributions of other items in the same questionnaire
proved difficult. Item data were not transformed to nor-
mality, thereby sacrificing some of the accuracy of reliabil-
ity and factor analyses for the convenience of having
interpretability of original units. The assumption was
made that if reliability were high, the factor analysis
robust, and the number of respondents sufficiently high,
then a degree of non-normality was acceptable. In sub-
group analyses, Mann-Whitney tests were performed on
skewed variables, and t-tests on normal data.
Internal consistency reliability and factor structure
Cronbach's alpha coefficient [36] was determined with an
acceptable minimum alpha being taken as 0.7 to 0.8,
depending on the number of items in a scale [37], noting
that some consider 0.9 as the minimum for measures of
differences between individuals [38]. Acceptable cor-
rected item-total correlations are those >0.2 [39]. Factor
structure was explored using Principal Components
extraction with Varimax rotation. Salient loadings were
taken as ≥ 0.4, higher than the recommended minimum
0.3 [40], erring on the side of caution in an effort to
reduce the risk of spurious loadings that owed their origin
to non-normality of item distributions and to avoid mul-
tiple loadings.
Subgroup differences and 'familywise' error in multiple tests
The questionnaires' sensitivity to some subgroup differ-
ences was investigated (GH-treatment groups, and sex).
The Holm's sequential Bonferroni procedure for multiple
tests [41] was adopted in large correlation matrices and
for the W-BQ12 and its subscales.
Concurrent validity
Correlations were undertaken with Mental Health, Vital-
ity and Physical Functioning subscales of the widely used
SF-36 health status measure also completed in this study
[32]. SF-36 subscale scores range from 0 to100, (higher
scores indicating better functioning). Correlations >0.7
indicated adequate convergence [42].
Means are reported as mean (standard deviation).
Study 2: Prospective study of GH-withdrawal
Preliminary sensitivity to change was assessed in a small
randomised, double-blind, placebo-controlled study
where severely GH-deficient patients were allocated to
placebo or continued treatment with GH for a period of
three months. This study has been fully described else-
where [33]. The GWBI and W-BQ-12 (in a battery of sev-
eral questionnaires) were completed at baseline and end-
point. There was a general clinical expectation of deterio-
ration in physiological factors during the study period for
those withdrawn from GH treatment and that this might
be accompanied by reduced psychological well-being.
The Guy's and St Thomas' Hospital Trust Ethics Commit-
tee gave approval for both studies and patients gave writ-
ten informed consent before participating. Research was
carried out in compliance with the Helsinki Declaration
Results
Cross-sectional study
The patient sample
Of 219 questionnaires distributed, 163 were returned
(74% response rate), but six patients did not meet allHealth and Quality of Life Outcomes 2006, 4:16 http://www.hqlo.com/content/4/1/16
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inclusion criteria, leaving 157 data sets, (91 GH-treated
and 66 non-GH-treated patients). Most patients (96%)
had multiple pituitary hormone deficiencies including
GHD; the remainder had isolated GHD. (See Table 1 for
sample characteristics).
Completion rates
The completion rates for the GWBI and W-BQ12 were
very high (99.1% and 99.0% respectively) indicating
excellent acceptability to respondents.
Table 1: Characteristics of the 157 patients in the cross-sectional survey
GH treatment
(Maximum N = 91)
No GH treatment
(Maximum N = 66)
Women 51 33
Men 40 33
Childhood onset of GHD 21 9
Adult onset of GHD 70 57
Isolated GHD 5 1
Multiple pituitary hormone deficiencies 86 65
Mean age (SD) in years 47.1 (12.59) 51.32 (12.41)
[range] [23.75–70.92] [23.83–70.92]
Mean duration GHD (SD) in years (adult onset patients) 13.02 (6.78) 13.18 (7.84)
Mean duration GH Treatment (SD) in years 3.6 (2.39) -
[range] [0.5–10.17] -
BMI (kg/m2) (SD) 27.16 (5.54) 27.99 (5.25)
Height (cms) (SD) 167.5 (10.53) 168.7 (10.6)
Table 2: GWBI loadings on unforced and forced 1-factor analyses‡
Question Factors in an unforced analysis Forced 1-factor
123
Q1 feel in general .586 .532 .222 .821
Q2 bothered by nerves* .669 .136 .104 .588
Q3 in firm control .678 .459 .026 .772
Q4 sad hopeless* .644 .373 .114 .724
Q5 under stress* .638 .066 .395 .620
Q6 happy with personal life .550 .486 .146 .740
Q7 losing control* .711 .082 .126 .591
Q8 anxious upset* .782 .220 .347 .801
Q9 wake up rested .284 .699 .231 .718
Q10 illness pain* .159 .304 .861 .592
Q11 life full of interest .316 .675 .090 .678
Q12 disheartened sad* .728 .382 .308 .853
Q13 stable sure .618 .545 .057 .795
Q14 tired exhausted* .351 .667 .374 .792
Q15 depressed* .744 .395 .250 .853
Q16 tense* .686 .365 .117 .749
Q17 well enough to do things .286 .632 .408 .737
Q18 energy vitality .147 .822 .275 .715
Q19 worries about health* .289 .376 .762 .695
Q20 active vigorous .194 .841 .265 .757
Q21 cheerful .616 .590 .063 .825
Q22 relaxed .645 .521 .109 .816
% of variance 30.8 25.9 11.0 55.1
‡Principal Components extraction.
*Negatively worded item scores have been reversed for comparison with factor analyses conducted by Gaston and Vogl [22].
Salient loadings ≥ 0.4. Loadings in bold are highest loadings for an item; italicised loadings are salient, but not the highest loading.Health and Quality of Life Outcomes 2006, 4:16 http://www.hqlo.com/content/4/1/16
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Reliability and factor analyses
GWBI
Unforced factor analysis of the whole scale produced
three factors with eigenvalues >1, accounting for 67.7% of
the variance (Table 2). These three factors were very simi-
lar to those obtained for a non-clinical population where
the factors were described as: Factor 1 ('general mood/
affect'), Factor 2 ('life satisfaction/vitality') and Factor 3
('poor physical health/somatic complaints') [22]. The
main differences between the factor loadings obtained on
the two studies were for item 14 tired exhausted, which
loaded highest on Factor 2 (present study) compared to
Factor 3 (non-clinical population), and item 6 happy with
personal life which loaded highest on Factor 1 (present
study), compared to Factor 2 (non-clinical sample). There
were double loadings >0.4 (present study) across factors
for seven items, with two more items potentially double
loading (at 0.395).
As the original PGWB has six subscales, and only minor
alterations were made when adapting the measure for use
in Britain, a forced 6-factor analysis was conducted to
investigate support for the original subscales. However,
GWBI items did not load separately as intended on the six
factors (Table 3). Factor 1 consisted of vitality items, with
one general health item (Q17), and Factor 2 consisted of
self-control, positive well-being and depression items.
Factor 3 was a mix of anxiety, depression and positive
well-being items. There was double loading of nine items
on more than one factor and, given the lack of any clear
pattern of loading, there was no support for a 6-subscale
structure. However, the single factor produced in a forced
1-factor analysis of the 22 items accounted for 55.1% of
the variance with all items loading satisfactorily ≥ 0.58,
(supporting calculation of the GWBI Total score) (Table
2). Note that the loadings in Tables 2 and 3 reflect the fact
that scores on negatively worded GWBI items have been
reversed to allow for ease of comparison with the results
obtained by Gaston and Vogl [22].
GWBI whole-scale reliability was very high, (Cronbach's
alpha 0.959, standardised item alpha 0.96, N = 152),
probably indicating some item redundancy. Corrected
item-total correlations ranged from 0.55 to 0.83 and were
very respectable, no item would increase scale alpha if
deleted. Reliability analysis of the three potential sub-
Table 3: GWBI loadings on forced 6-factor analyses ‡
Question Factors
123456
Q1 feel in general .424 .437 .282 .386 .216 .203
Q2 bothered by nerves* .113 .233 .207 .153 .117 .878
Q3 in firm control .343 .447 .279 .385 .027 .384
Q4 sad hopeless* .220 .698 .100 .390 .179 .146
Q5 under stress* .063 .216 .749 .135 .294 .099
Q6 happy with personal life .298 .225 .531 .524 .129 -.015
Q7 losing control*. 1 3 2 .807 .284 -.009 .068 .107
Q8 anxious upset* .204 .523 .530 .181 .286 .274
Q9 wake up rested .686 .156 .201 .258 .157 .156
Q10 illness pain* .314 .090 .183 .107 .855 .024
Q11 life full of interest .357 .056 .095 .746 .210 .166
Q12 disheartened sad* .267 .426 .500 .386 .289 .225
Q13 stable sure .340 .488 .200 .539 .112 .197
Q14 tired exhausted* .705 .175 .357 .183 .254 .124
Q15 depressed* .321 .490 .412 .314 .223 .339
Q16 tense* .421 .288 .649 .114 -.043 .313
Q17 well enough to do things .690 .211 .150 .120 .325 .239
Q18 energy vitality .828 .184 .106 .239 .189 -.036
Q19 worries about health* .350 .196 .168 .191 .775 .147
Q20 active vigorous .799 .157 .091 .328 .213 .078
Q21 cheerful .369 .412 .357 .592 .087 .069
Q22 relaxed .377 .193 .497 .474 .080 .347
% variance 19.9 14.2 13.4 12.8 9.5 7.5
‡Principal Components extraction.
*Negatively worded item scores have been reversed for comparison with factor analyses conducted by Gaston and Vogl [22].
Salient loadings ≥ 0.4. Loadings in bold are highest loadings for an item; italicised loadings are salient, but not the highest loading.Health and Quality of Life Outcomes 2006, 4:16 http://www.hqlo.com/content/4/1/16
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scales (items loading highest on each factor in the
unforced analysis, Table 2) indicated that Cronbach's
alpha for the 14 items on Factor 1 (general mood/affect)
was 0.949 (N = 154), for the six items on Factor 2 (life sat-
isfaction/vitality) was 0.905 (N = 155) and for the two
items on Factor 3 (poor physical health/somatic com-
plaints) was 0.874 (N = 154).
Investigating possible item redundancy further, some
items are similar in wording e.g. 'fears about health'
appears in Q10 (Have you been bothered by any illness, pains
or fears about your health?) and Q19 (Have you had any wor-
ries or fears about your health?); 'sad' is found in Q4 (Have
you felt sad, discouraged or hopeless, so much so that you won-
dered if life was worthwhile?) and Q12 (Have you felt dis-
heartened and sad?). When the unforced factor analysis was
conducted with either item Q10 or Q19 deleted from the
scale, two factors emerged, with the health item (Q10 or
Q19) loading (>0.6) on Factor 2, and the remaining items
loading as for the original 22-item scale.
W-BQ12
The single factor produced in a forced 1-factor analysis,
where all items loaded ≥ ± 0.6, accounted for 56.3% of the
variance, confirming the validity of the W-BQ12 General
Well-being total score. An unforced factor analysis of the
whole scale produced two components with multiple
loadings (results not shown). A forced 3-factor analysis
(74.6% of the variance) found the four Positive Well-
being items and the two positively worded Energy items
loading on Factor 1 at >0.4; all four Negative Well-being
items loaded on Factor 2 and all four Energy items loaded
on Factor 3 with Negative Well-being item 2 (Table 4).
There was some double loading found for items 2, 5 and
8. Forced 1-factor analyses of subscales found all items
loading >0.8 on their respective subscales, confirming the
acceptability of calculating subscale scores.
A high Cronbach's alpha (0.93) was obtained for the
whole scale (N = 148). Corrected item-total correlations
were satisfactory (>0.5). The alpha coefficients were very
high for each of the 4-item subscales: Negative Well-being
(0.86, N = 153), Energy (0.86, N = 152) and Positive Well-
being (0.88, N = 154), with corrected item-total correla-
tions >0.65. No item would increase scale or subscale
alpha if deleted.
Subgroup differences
There were no significant differences in well-being
between GH-treated and non-GH-treated patients. Mean
GWBI Total of GH-treated patients was 51.2 (S.D. 15.51)
and of non-GH-treated patients was 50.89 (17.4) (p =
0.91, t-test); mean W-BQ12 General Well-being total of
GH-treated patients was 21.84 (S.D. 8.15) and of non-
GH-treated patients was 23.18 (8.43) (p = 0.32, t-test).
Nor were significant differences found between those with
childhood onset GHD (N = 29) and adult onset (N =
127). Mean GWBI Total of patients with childhood-onset
GHD was 52.9 (S.D. 19.2) and those with adult-onset was
50.67 (15.61) (p = 0.52, t-test); mean W-BQ12 General
Well-being total of patients with childhood-onset GHD
was 20.66 (S.D. 8.77) and of those with adult-onset was
22.8 (8.14) (p = 0.21, t-test). Men had significantly better
overall well-being than women (GWBI Total and W-BQ12
General Well-being total) and significantly reduced W-BQ
Negative Well-being compared with women, (see Table
5).
Correlations with duration of GH treatment
There were significant negative correlations between dura-
tion of GH treatment and GWBI Total (r = -0.36, p =
0.001, N = 85) and W-BQ12 Negative Well-being (rho = -
0.37, p < 0.001, N = 88) and significant positive correla-
tions (N = 88) with W-BQ12 Total (r = 0.35, p = 0.001),
Positive Well-being (r = 0.33, p = 0.002), and Energy (r =
0.23, p = 0.029). Thus, the longer the duration of GH
treatment (ranging from 0.5 to 10 years in this patient
sample), the better the well-being.
Concurrent validity with SF-36 subscales
GWBI Total correlated strongly and negatively with SF-36
Mental Health (-0.83) and Vitality (-0.82) but had lower
correlations with Physical Functioning (-0.47) as might be
expected. W-BQ12 General Well-being total correlated
strongly with SF-36 Mental Health (0.80). W-BQ12
Energy correlated highly with Vitality (0.80); W-BQ12
Positive Well-being and Negative Well-being correlated
moderately highly with SF-36 Mental Health (0.73 and -
0.74 respectively), but their correlations with Physical
Functioning were lower (-0.31 to 0.49) as expected. Neg-
ative correlations were obtained, as expected, where ques-
tionnaires are scored in the opposite direction. Note: all
correlations were Spearman's rho and significant, p
<0.001, 2-tailed, N ranged from 142 to 157.
GH-Withdrawal study
The data of 21 patients (age range 25–68 years), all but
two with multiple pituitary hormone deficiencies, were
available for analysis: 12 placebo-treated (6 men and 6
women) and nine GH-treated (4 men and 5 women).
Three months after baseline the serum total Insulin-like
Growth Factor-I of placebo-treated patients fell from nor-
mal, age-related levels, mean 26.6 (13.2) nmol/L, to levels
indicative of severe GHD, 11.6 (6.7) nmol/L, (p <0.001).
Only a small, non-significant decrease was noted in GH-
treated patients. Full details are provided elsewhere [33].
Completion rates of both GWBI and W-BQ12 were 100%
in this study. A significant between-group difference in
change scores in W-BQ12 Energy was found [t(18) = 3.25,Health and Quality of Life Outcomes 2006, 4:16 http://www.hqlo.com/content/4/1/16
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p = 0.004, 2-tailed] with scores of Placebo-group patients
dropping from 6.83 (3.64) at baseline to 5.9 (4.12) at
end-point, indicating reduced energy, while GH-treated
patients' scores increased from 7.06 (2.08) to 8.13 (1.25)
over this period. GWBI Total showed no significant
change (p = 0.24).
Discussion
The two studies described here have made a useful contri-
bution towards the psychometric validation of two well-
being questionnaires for use in adult growth hormone
deficiency: the General Well-being Index and the 12-item
version of the Well-being Questionnaire.
Despite only minor changes made to a few words and to
item order when adapting the Psychological General
Well-being Index for use in Britain [19], a forced 6-factor
analysis of the British GWBI did not find the 22 items fac-
toring out separately into PGWB subscales such as anxiety
or self-control. Unforced factor analysis, however, pro-
duced three factors (albeit with substantial double load-
ing), largely confirming the factors labelled as 'general
mood/affect', 'life satisfaction/vitality', 'poor physical
health/somatic complaints' in the earlier study by Gaston
and Vogl, conducted with a non-clinical sample [22].
GWBI Factor 1 items (present study) covered several
aspects of affect, and positive and negative well-being did
not factor out separately as in the W-BQ12. Vitality
(GWBI) items loaded together with positive well-being on
Factor 2, but with the W-BQ12, the value of having a sep-
arate energy subscale was demonstrated in that W-BQ12
Energy was the only scale sensitive to change in the GH-
Withdrawal study. Although the GWBI has a weak physi-
cal health factor, accounting for just 11% or the variance,
this reflects the fact that one of the six subscales of the
original PGWB concerned general health. However, the
GWBI could not be described as a measure of health status
as only a small proportion of items (3/22) concern phys-
ical health perceptions.
The internal consistency reliability of the whole GWBI
scale was very high (>0.95) indicating that there may well
be redundancy of items, particularly as two pairs of items
are similarly worded, adding unnecessarily to respondent
burden. The two general health items loading on Factor 3
in the unforced factor analysis had similar wording, and
one or the other would appear to be redundant (if either
were deleted from the scale then only two factors emerged
in the unforced analysis). Although the reliability of the
three potential GWBI subscales was high, overlap is con-
siderable and we agree with the recommendation by McK-
enna et al [20] that there are no clear subscales to the
questionnaire, and only a total score should be calculated.
Factor analysis of the W-BQ12 indicated three relatively
clean factors providing evidence for W-BQ12 subscales of
Negative Well-being and Positive Well-being and,
although two W-BQ12 Energy items double loaded, it was
possible to interpret the third W-BQ12 factor as an Energy
subscale. There was support for the calculation of a total
score for the questionnaire. The internal consistency relia-
bility of subscales and W-BQ12 General Well-being com-
bined scale was excellent. This high value would not
indicate item redundancy, however, (as in the case of the
Table 4: W-BQ12 loadings on forced 3-factor and 1-factor analyses ‡
Item (subscale) Factors in forced 3-factor analysis Forced 1-factor analysis
123
1: crying spells*(Negative Well-being) -.357 .753 .185 -.732
2: downhearted* (Negative Well-being) -.313 .575 .511 -.773
3: afraid no reason* (Negative Well-being) -.125 .866 .127 -.603
4: upset panicky* (Negative Well-being) -.248 .805 .213 -.698
5: energetic active (Energy) .691 -.130 -.436 .763
6: dull sluggish* (Energy) -.321 .260 .825 -.772
7: worn out* (Energy) -.291 .210 .862 -.744
8: wake rested (Energy) .646 -.135 -.449 .742
9: happy (Positive Well-being) .711 -.325 -.327 .823
10: lived life wanted (Positive Well-being) .769 -.287 -.176 .768
11: eager tackle tasks (Positive Well-being) .829 -.172 -.285 .803
12: cope (Positive Well-being) .772 -.350 -.093 .761
% variance 31.37 23.18 19.99 56.3
‡Principal Components extraction.
*Negatively worded items, the raw scores of which have not been reversed.
Salient loadings ≥ 0.4. Loadings in bold are highest loadings for an item; italicised loadings are salient, but not the highest loading.Health and Quality of Life Outcomes 2006, 4:16 http://www.hqlo.com/content/4/1/16
Page 8 of 10
(page number not for citation purposes)
GWBI), because the W-BQ12 is considerably shorter than
the GWBI and none of the items are similar to each other
(as in the GWBI).
Both well-being questionnaires had very high completion
rates indicating good acceptability to patients, an indica-
tion of face validity. The strong correlations of both ques-
tionnaires with appropriate scales of the SF-36 (Mental
Health and Vitality) but lower correlations with SF-36
Physical Functioning gave support for the concurrent
validity of both questionnaires. The moderate correla-
tions with Physical Functioning, however, indicate that
well-being is associated with some aspects of health sta-
tus.
There was preliminary evidence for construct validity in
both GWBI and W-BQ12, although no prior hypotheses
were formulated. Both questionnaires found significant
differences between men and women, with women hav-
ing generally lower well-being than men. It is a common
finding that, in the general population, women have
reduced well-being compared with men [43,44], although
not all studies have found this [21]. Women with GHD
have also tended to exhibit lower levels of well-being than
men [10]. Both questionnaires showed correlations indic-
ative of improving well-being for GH-treated patients
with longer periods of GH treatment, as seen in previous
research [17]. However, neither questionnaire found sig-
nificant GH treatment-group differences either because
the questionnaires were insufficiently sensitive to treat-
ment-group differences, or there were no real differences
in well-being between the two groups, possibly as a result
of the fact that symptomatic patients were more likely to
have been selected for treatment by the doctors in the clin-
ics. Indeed none of the other questionnaires used in the
study found GH-treated patients to have significantly bet-
ter patient-reported outcomes (including health status
and condition-specific quality of life) than non-treated
patients [34]. It is possible, but perhaps more unlikely,
that those receiving GH were not all adhering to the injec-
tion regimen (the patients' Insulin-like Growth Factor-I
data at the time of the study were not collected).
The small sample size in the GH-Withdrawal study
resulted in low power of analysis but, as anticipated, W-
BQ12 Energy found a significant between-treatment-
group difference in change scores over the withdrawal
period, with reduced energy in placebo-treated patients at
end-point. This provided a very preliminary indication of
the W-BQ12's sensitivity to change, (there was no signifi-
cant finding for the GWBI). This is in line with results of a
study in which GH was discontinued in young adults with
GHD [45] where a significant increase in psychological
complaints (on the Hopkins Symptom Checklist [46])
was found after 6 months' discontinuation, although not
across 12 months' discontinuation. It is possible that the
3-month withdrawal period of the present study was not
long enough for significant change to be registered by the
GWBI. All the previous studies of GH-replacement ther-
apy that found significant improvement in psychological
well-being using the PGWB, had a minimum 6 months'
duration [13,14,17]. Further work on sensitivity to change
with this patient group would be valuable in a larger and
longer-term longitudinal intervention study, where GH
treatment is being offered, not withdrawn.
The American PGWB has been the most widely used
measure of psychological well-being in adult GHD, its six
subscales sensitive to change in several studies of GH
replacement. The British GWBI, on the hand, has no sub-
scales, and the present study has confirmed that none can
be recommended. This could be a disadvantage in this
hormonal condition where low energy, increased anxiety
and depression are key psychological aspects. Therefore,
Table 5: Means for men and women in the cross-sectional survey
Men Women Significance of differences
Mean (SD) [Median]
(Minimum N = 71)
Mean (SD) [Median]
(Minimum N = 81)
GWBI Total 48.07 (15.27) [47] 53.70 (16.76) [52] t(150) = -2.15, p = 0.033
W-BQ12
General Well-being total 24.50 (7.86) [25] 20.55 (8.23) [21] t(154) = 3.05, p = 0.003
Negative Well-being 1.84 (2.32) [1] 3.68 (2.89) [3] U = 1853.5, p < 0.001, N = 157
Energy 6.87 (3.32) [7] 5.92 (3.20) [6] n.s (p = 0.07)
Positive Well-being 7.47 (3.16) [8] 6.36 (3.33) [7] n.s (p = 0.035)*
GWBI: score range 22 – 110 (lower score indicates better well-being).
W-BQ12: subscale score range 0 – 12 (higher scores indicating increased mood of the subscale label); General Well-being total range 0 – 36 (higher 
score indicating better well-being).
*Not significant after Bonferroni correction (required p value of 0.05/3 = 0.017) applied.Health and Quality of Life Outcomes 2006, 4:16 http://www.hqlo.com/content/4/1/16
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on the evidence provided by the present studies, the W-
BQ12 can be recommended in preference to the GWBI to
measure psychological well-being in adult GHD because
the W-BQ12 has:
• excellent reliability, both of the whole scale and of the
three subscales, with no indication of item redundancy;
• a clear factor structure supporting the use of subscales of
Negative Well-being, Energy and Positive Well-being;
• fewer items (12 compared with 22 in the GWBI) and
shorter response options (these are relatively long and
vary from item to item in the GWBI, causing greater
respondent burden);
• preliminary evidence of sensitivity to change.
To cover a wider range of patient-reported outcomes in
adult GHD, it is recommended that the generic W-BQ12
be used in a battery of questionnaires that includes a
generic measure of health status (e.g. the SF-36 [31]) and
the HDQoL hormone deficiency-specific quality of life
questionnaire [5].
Conclusion
The W-BQ12 is recommended in preference to the GWBI
to measure well-being in adult GHD as it is shorter, has
useful subscales, has excellent internal consistency relia-
bility with no indication of redundancy of items, and has
preliminary indications of sensitivity to change.
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